Trial Profile

A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infection

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jul 2026 Status changed from planning to recruiting.
15 May 2026 Planned number of patients changed to 68.
24 Feb 2026 According to a Centauri Therapeutics media release, the company has secured euro 6M from AMR Action Fund, extending the Company's Series A round to euro 30M. The investment will support the completion of Phase I clinical studies for CTX-187, Centauri's ead clinical candidate in the ABX-01 programme, and will expand the scope of additional research activities in preparation for Phase II.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com